Tegafur Suppository

This product is a derivative of fluorouracil. It is activated by the liver in the body and gradually converted into fluorouracil to play an anti-tumor role. It can interfere with and block the synthesis of DNA, RNA and protein, and mainly acts on the S phase. It is a cell cycle-specific drug of the anti-pyrimidine class. Its mechanism of action, efficacy and anti-tumor spectrum are similar to those of fluorouracil, but it has a long-lasting effect, good absorption and low toxicity. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. No severe bone marrow suppression was observed in the chronic toxicity test, and the effect on immunity was relatively mild.

1-(Tetrahydro-2-furyl)-5-fluoro-2,4(1H,3H)-pyrimidinedione.

This product is an off-white or slightly yellow suppository.

Clinical indications: colon cancer, rectal cancer, large intestine cancer, gastric cancer, esophageal cancer, head and neck cancer, breast cancer, primary liver cancer, lung cancer, pancreatic cancer, prostate cancer. First choice: colon cancer, rectal cancer, large intestine cancer, gastric cancer, esophageal cancer. Second choice: head and neck cancer, breast cancer, primary liver cancer. Others: lung cancer, pancreatic cancer, prostate cancer.

For rectal administration: 500 mg (1 tablet) at a time, 1 to 2 times a day.

Bone marrow suppression reaction is mild, with a decrease in white blood cells and platelets. Neurotoxic reactions include headache, dizziness, ataxia, mental status changes, etc. A few patients have nausea, vomiting, diarrhea, and changes in liver and kidney function. Fever, skin itching, and pigmentation are occasionally seen.

1 Pregnant and lactating women are prohibited from using this product. 2 People who are allergic to this product should use it with caution.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

Not yet clear.

Keep away from light, tightly closed, in a cool place.

0.5g*10s

24 months

Chengdu First Pharmaceutical Co., Ltd.

• Founded in:

  2013-11-14

• Address:

  No. 133, Section 2, East Third Ring Road, Tianpeng Town, Pengzhou City, Sichuan Province

• Tax NO.:

  91510182083307998R

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view